Human Oncology & Pathogenesis Program

The Michael Berger Lab

Research

Michael F. Berger, PhD

Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology

The focus of the Berger laboratory is to characterize the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response.

View Lab Overview

Featured News

Finding

Secondary Leukemia: Research Suggests New Ways to Understand What Causes This Side Effect of Cancer Treatment

Thursday, August 10, 2017

Finding

Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs

Monday, November 17, 2014

Landmark $100 Million Gift from the Marie-Josée and Henry R. Kravis Foundation Supports a Groundbreaking Approach to Precision Oncology

Sunday, June 1, 2014

View All Featured News

Publications

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit DB, Klimstra DS, Hyman DM, Taylor BS, Berger MF. JAMA Oncol. 2019 Nov 14.

Tumour lineage shapes BRCA-mediated phenotypes. Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O’Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS. Nature. 2019 Jul;571(7766):576-579.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF*, Mellinghoff IK*. Nature. 2019 Jan;565(7741):654-658.

View All Publications

People

Michael F. Berger, PhD

Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology

Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
PhD, Harvard University

[email protected]: Email Address
646-888-3386: Office Phone
View physician profile: Physician profile

Members

Kanika Arora

Senior Computational Biologist

Mukta Asnani

Senior Research Assistant, CMO Technology Innovation

Viswatej Avutu

Fellow

David Brown

Senior Computational Biologist, CMO Technology Innovation

Sebastià Franch Exposito
Research Fellow

Adrian Fraiha
Bioinformatics Software Engineer, cfDNA Informatics

Maysun Hasan, Computational Biologist, CMO Technology Innovation — Maysun Hasan
Computational Biologist, CMO Technology Innovation

Ian Johnson, Bioinformatics Engineer — Ian Johnson
Bioinformatics Engineer, CMO Technology Innovation

Brian Houck- Loomis, Manager, CMO Technology Innovation — Brian Loomis
Manager, CMO Technology Innovation

Fanli Meng
Research Lab Manager, CMO Technology Innovation

Kamal Menghrajani

Assistant Attending

Charles Murphy

Senior Computational Biologist, cfDNA Informatics

Johnathan Rafailov

Bioinformatics Tech

Ronak Shah
Principal Computational Biologist, cfDNA Informatics

Shalabh Suman
Senior Computational Biologist

Grittney Tam
Senior Research Assistant, CMO Technology Innovation

Giang Vo

Research Assistant, CMO Technology Innovation

Lab Alumni

Angela Rose Brannon, PhD — Angela Rose Brannon
Research Fellow

Niedzica Camacho-Ordonez
Research Fellow

Xiaohong Jing
Lab Manager, CMO Technology Innovation

Juber Ahamad Patel
Computational Biologist, CMO Technology Innovation

Dilmi Perera, Research Fellow — Dilmi Perera
Research Fellow

Jonathan Reichel
Computational Biologist, CMO Technology Innovation

Jiabin Tang
Group Leader, Innovation Laboratory

Helen Won, MS — Helen Won
Computational Biologist

Lab Affilations

Open Positions

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email
646-888-3386

Office Phone
Twitter Profile

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael F. Berger discloses the following relationships and financial interests:

Advances in Genome Biology and Technology (AGBT)
Provision of Services (uncompensated)
American Association for Cancer Research
Provision of Services (uncompensated)
American Society of Clinical Oncology (ASCO)
Provision of Services
Cold Spring Harbor Laboratory
Provision of Services (uncompensated)
Cycle for Survival
Provision of Services (uncompensated)
European Molecular Biology Laboratory
Provision of Services (uncompensated)
European Society for Medical Oncology (ESMO)
Provision of Services (uncompensated)

Fox Chase Cancer Center
Provision of Services
Hospital Sirio-Libanes
Provision of Services
JCO Precision Oncology
Provision of Services (uncompensated)
Journal of Molecular Diagnostics
Provision of Services (uncompensated)
Journal of Visualized Experiments
Provision of Services (uncompensated)
Qiagen
Provision of Services (uncompensated)
Stand Up to Cancer
Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures